<p>OrganiGram Global Inc. reported significantly higher international sales in the most recent fiscal year compared to the previous year, driven by efficiencies in production, manufacturing, and logistics. The company achieved an adjusted gross margin of 38% in the fourth quarter and maintained this margin in the first quarter of the new fiscal year despite lower international sales. OrganiGram’s growth strategy includes a strong innovation pipeline, improving cannabis quality, higher potency products, and the commercialization of its FASTTM nanoemulsion technology in ingestible formats. The company also anticipates further growth through mergers and acquisitions, particularly focusing on international opportunities to expand branded product sales and strengthen competitiveness in Canada. The full report can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrganiGram Global Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-006658), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

OrganiGram Global Inc. Releases MD&A for Three Months Ended December 31, 2025